CU Anschutz Medicine Chair Will Step Down in October
The University of Colorado School of Medicine will transition leadership in its department of medicine starting October 26.
Updated on Oct. 12, 2026 in People
Live Poll
Should your local university prioritize research funding growth as a primary measure of departmental success?
Dr. Vineet Chopra will step down as chair of the Department of Medicine at the University of Colorado Anschutz School of Medicine on October 26, 2026. He will continue to serve as executive vice dean for clinical, quality, and research while Mark Earnest takes over as interim chair.
Why it matters
The leadership change follows a period of growth that saw the department's national NIH funding rank improve from 23rd to 14th. This shift marks a transition in oversight for a department managing over one million annual patient visits.
The department currently supports 192 residents and 200 fellows, fueled by $162 million in research awards in 2025. It oversees a massive clinical operation with more than one million patient visits annually.
The players
Dr. Vineet Chopra
An academic medical leader currently serving as chair of the Department of Medicine and executive vice dean at the University of Colorado Anschutz School of Medicine.
Mark Earnest
An academic physician who will serve as the interim chair of the University of Colorado Department of Medicine.
The details
Under Dr. Chopra's tenure, the department utilized data to formalize clinical performance metrics, salary equity, and promotion criteria. These processes were paired with a fivefold increase in research investment over the last five years. Mark Earnest will assume interim responsibilities as the institution maintains these operational standards for research and residency support.
Timeline
May 2025: Dr. Chopra was appointed interim executive vice dean.
2025: Faculty received $162 million in research awards.
October 26, 2026: Dr. Chopra will step down as department chair.
Market Landscape
This leadership change follows the department's advancement to 14th in national NIH funding, up from 23rd. The move aligns with the institution's ongoing focus on data-driven clinical performance and research growth strategies.
Operators managing large clinical or research departments should watch how the institution balances the interim leadership transition with its current data-driven performance mandates. Maintain focus on ongoing research award metrics and residency support capacities during the changeover.
The takeaway
Large-scale organizational success often requires shifting from aggressive growth initiatives to maintaining established data-driven infrastructure. Watch how the department's performance metrics trend under the new interim leadership as a benchmark for operational continuity.
Further reading
For more on administrative shifts in the region, visit the People section.
Source note: This article includes information reported by The American Bazaar.
Live Poll
Should your local university prioritize research funding growth as a primary measure of departmental success?
